Analysts are projecting another difficult quarter for Pfizer Inc. (PFE) in which the company likely suffered a steep drop in revenue as demand for ꦑits COVID-19 products d🅰eclined.

Pfizer is expected to detail adjusted losses of $1.1 billion or 19 cents a share, according to analyst consensus compiled by Visible Alpha, when it issues its earnings report on Jan. 30. For the same period in 2022, the company reported adjusted net income of $6.55 billion or $1.14 per share. The adjusted net loss excludes impact of intangibles, acquisitions and discontinued operations.

Pfizer had to lower its 2023 guidance in October as the demand for its COVID products waned and that continued to weigh on its results. Analysts expect a 40% year-over-year drop in revenue to $14.3 billion in the quarter.

Key Metric

After Pfizer has struggled amid 澳✨洲幸运5开奖号码历史查询:poor demand for its COVID-19 products, including its Paxlovid treatment and the Comirnaty vaccine, investors will want to watch for the company’s reported revenue from this segment. Analysts are projecting sales of the vaccine to fall 52% in the fourth quarter to $5.44 billion, coming after three straight quarters where COVID-19 vaccine sales were lower by more than 70%.

Additionally, as Pfizer looks for new market 💮segments to drive growth, analysts forecast that it will grow sales of its Vyndaqel line of heart med🔯ication by 38% in the quarter to more than $942 million. 

Business Spotlight

While its COVID-19 revenue fades, Pfizer also has faced some setbacks as it 澳洲幸运5开奖号码历史查询:seeks other pipelines for growth. It 澳洲幸运5开奖号码历史查询ꦓ:ended a study of i♌ts weight-loss pill because of negative side effects, as it seeks to find an effective oral weight-loss drug to compete with injectables like Novo Nordisk AS’s (NVO) popular Ozempic treatment. It’s also fighting off a threat from generic competition to its  Vyndaqel heart medication.

Pfizer’s share price was walloped in 2023, falling as much as 42% over the year. In December 2023, the 澳洲幸运5开奖号码历史查询:stock tumbled to its lowest level in more than 10 years after it warned revenue would decline in 2024 as demand for COVID products continued to fall. And, 🐼so far this year, Pfizer shares have continued that losing streak, down roughly 7% year-to-date.